BRIEF published on 08/12/2026 at 14:00, 1 hour 55 minutes ago Revive Therapeutics Announce Positive Study Results on Bucillamine for Nerve-Agent Exposure Bucillamine Revive Therapeutics Nerve-agent Research DRDC Study Biodefence
BRIEF published on 08/12/2026 at 14:00, 1 hour 55 minutes ago Revive Therapeutics annonce des résultats d'étude positifs sur la bucillamine pour l'exposition aux agents neurotoxiques Biodefense Bucillamine Revive Therapeutics Recherche Sur Les Agents Neurotoxiques Étude Du DRDC
PRESS RELEASE published on 08/12/2026 at 13:55, 2 hours ago Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study Revive Therapeutics announces positive results from DRDC research study on bucillamine in nerve-agent exposure model, showing preservation of GABA receptors. Further studies planned Bucillamine Revive Therapeutics DRDC Research Study Nerve-agent Exposure GABA Receptors
BRIEF published on 07/16/2026 at 00:45, 27 days 15 hours ago Revive Therapeutics Completes First Tranche of Private Placement Private Placement Life Sciences Shares And Warrants Funding Initiative Revive Therapeutics
BRIEF published on 07/16/2026 at 00:45, 27 days 15 hours ago Revive Therapeutics finalise la première tranche de placements privés Placement Privé Sciences De La Vie Actions Et Bons De Souscription Initiative De Financement Revive Therapeutics
PRESS RELEASE published on 07/16/2026 at 00:40, 27 days 15 hours ago Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement Revive Therapeutics Ltd. closes the first tranche of non-brokered private placement, raising $246,920 for infectious diseases and medical countermeasures research and development Private Placement Research And Development Medical Countermeasures Infectious Diseases Revive Therapeutics Ltd.
BRIEF published on 06/26/2026 at 22:20, 1 month 15 days ago Revive Therapeutics Proposes Private Placement to Raise $1 Million Private Placement Shares Life Sciences Investment Revive Therapeutics
BRIEF published on 06/26/2026 at 22:20, 1 month 15 days ago Revive Therapeutics propose un placement privé pour lever 1 million de dollars Investissement Actions Placement Privé Sciences De La Vie Revive Therapeutics
PRESS RELEASE published on 06/26/2026 at 22:15, 1 month 15 days ago Revive Therapeutics Announces Proposed Private Placement Revive Therapeutics Ltd. announces a private placement offering of up to 31,250,000 units. The gross proceeds may reach approximately $1,000,000 for working capital Private Placement Working Capital Units Gross Proceeds Revive Therapeutics Ltd.
BRIEF published on 05/20/2026 at 13:50, 2 months 23 days ago Revive Therapeutics Expands Bucillamine Program for Broader Applications Strategic Partnerships Infectious Diseases Defense Applications Patent Expansion Bucillamine
Published on 08/12/2026 at 15:42, 13 minutes ago Critical Elements 10,000-Meter Summer Drill Program at Rose West Resumes with Positive Results
Published on 08/12/2026 at 15:42, 13 minutes ago Critical Elements redémarre son programme de forage estival de 10 000 mètres à Rose Ouest avec des résultats positifs
Published on 08/12/2026 at 15:00, 55 minutes ago Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America
Published on 08/12/2026 at 14:45, 1 hour 10 minutes ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/11/2026 at 17:45, 22 hours 10 minutes ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 22 hours 15 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 1 day 21 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 1 day 21 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
